A clinical study to evaluate the pharmacokinetics, efficacy, and safety of belumosudil in Chinese adolescents with cGVHD who have had an inadequate response to glucocorticoids or other systemic therapies

Trial Identifier: ACT18369
Sponsor: Sanofi
Start Date: December 2024
Primary Completion Date: May 2026
Study Completion Date: May 2026
Condition: Graft Versus Host Disease

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China, 100045
China Shanghai, China, 200127